Cargando…

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

INTRODUCTION: Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which included a low percentage of underweight patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Bravo Villa, Verónica, Romero, Job, Rojas‐Zaldivar, Eunice, Cervantes, Martha, Villa‐Márquez, María del Rosario, Baz, Patricia, Cesarman‐Maus, Gabriela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles ‐ Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035794/ https://www.ncbi.nlm.nih.gov/pubmed/33870027 http://dx.doi.org/10.1002/rth2.12492

Ejemplares similares

An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta‐analysis
por: Forgo, Gabor, et al.
Publicado: (2021)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
por: Jordan Bruno, Ximena, et al.
Publicado: (2022)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation
por: Li, Yanni, et al.
Publicado: (2020)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
por: van Dam, Lisette F., et al.
Publicado: (2021)

Safety and effectiveness of apixaban compared to warfarin in dialysis patients
por: Reed, Daniel, et al.
Publicado: (2018)

Post‐thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study
por: de Kleijn, Robert J. C. M. F., et al.
Publicado: (2022)

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE
por: Cohen, Omri, et al.
Publicado: (2021)

Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower‐leg injury or knee arthroscopy
por: Mohammed, Yassene, et al.
Publicado: (2022)

Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review
por: Notten, Pascale, et al.
Publicado: (2021)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study
por: Overvad, Thure F., et al.
Publicado: (2022)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study
por: Crobach, Monique J. T., et al.
Publicado: (2023)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen
por: Bar Barroeta, Awital, et al.
Publicado: (2022)

Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis
por: Madeeva, Daria V, et al.
Publicado: (2021)

COVID-19 coagulopathy, thrombosis, and bleeding
por: Chan, Noel C., et al.
Publicado: (2020)

Racial disparities in cancer-associated thrombosis
por: Datta, Tatini, et al.
Publicado: (2022)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Histidine-rich glycoprotein attenuates catheter thrombosis
por: Malik, Rida A., et al.
Publicado: (2023)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
por: Wanat, Matthew A., et al.
Publicado: (2019)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

The incidence of cancer-associated thrombosis is increasing over time
por: Mahajan, Anjlee, et al.
Publicado: (2022)

Thrombocytopenia with and without Thrombosis Following COVID-19 Vaccination
por: Ge, Melissa, et al.
Publicado: (2021)

Deep Vein Thrombosis after COVID-19 Vaccinations
por: Houghton, Damon E., et al.
Publicado: (2021)

The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis
por: Hsu, Charles, et al.
Publicado: (2022)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Oxidative stress mediated platelet activation in patients with congenital analbuminemia: Effect of albumin infusion
por: Baratta, Francesco, et al.
Publicado: (2021)

Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C
por: Whitworth, Hilary, et al.
Publicado: (2021)

Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis
por: Craven, Brian, et al.
Publicado: (2022)

Inhibition of NADPH oxidase blocks NETosis and reduces thrombosis in heparin-induced thrombocytopenia
por: Leung, Halina H. L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f1al5nvijcohgjtsd8l2og7qbj